Anti-Inflammatory Drugs for Mild Alzheimer's Disease

"Affirmative. According to clinicaltrials.gov, this research is looking for 90 individuals across 5 locations, with the original posting on October 28th 2021 and most recent update occurring November 11th 2022."

"This medical trial seeks ninety individuals with alzheimer disease, aged between 45 and 90 years old. Candidates should be male or female, have a reliable caretaker to accompany them to each visit, meet the criteria of probable MCI due to AD or mild AD according to the NIA-AA standards; present CSF sampling results that confirm amyloid and tau positivity at screening phase; demonstrate Mini-Mental State Examination (MMSE) scores ranging from 20 to 24 inclusive OR MMSE score of 25 - 30 inclusively plus DSST performance 0.5 SD below normative data at screening stage as well."

"At present, 5 clinical trial sites are actively enrolling patients. These locations can be found in Stony Brook, Fairfax and Knoxville as well as two other places. To minimize travel requirements if you choose to participate, select the closest site to your current residence."

"Presently, Canakinumab is the subject of 16 open trials conducted in 263 urban centres and 52 nations. The inaugural trial for this Novartis Pharmaceuticals-sponsored drug commenced back in 2018 with 1382 participants progressing to Phase 3 approval. Subsequently, 18363 have been concluded since then."

"Although there is limited data suggesting the efficacy of Canakinumab, our team at Power has assigned it a rating of 2 due to its safety profile in Phase 2 trials."

"Canakinumab is a viable treatment for Muckle-Wells Syndrome, Active Systemic Juvenile Idiopathic Arthritis and Neonatal-Onset Multisystem Inflammatory Disease (NOMID)."

"According to the criteria outlined in this trial, it is necessary that participants are aged at least 45 and no older than 90."

"Affirmative. Per the data hosted on clinicaltrials.gov, this medical study is recruiting patients as of 11/11/2022 after being initially posted on 10/28/2021. The research team require 90 participants to be enrolled from 5 difference sites."

"Currently, 16 studies on Canakinumab are underway with 3 trials in their final stage. The bulk of these investigations are based out of Houston, Texas but there is a total of 609 investigative sites for this medication."